Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies

被引：0

作者：

Yosipovitch, Gil ^{[1
]}

Staender, Sonja ^{[2
]}

Metz, Martin ^{[3
]}

Pink, Andrew E. ^{[4
]}

Silverberg, Jonathan, I ^{[5
]}

Sofen, Howard ^{[6
]}

Ahmed, Faiz ^{[7
]}

Noda, Aliene ^{[8
]}

Lopez, Zarif K. Jabbar ^{[8
]}

Piketty, Christophe ^{[8
]}

Kwatra, Shawn G. ^{[9
,10
]}

机构：

[1] Univ Miami, Miami Itch Ctr, Miller Sch Med, Miami, FL USA

[2] Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany

[3] Charite, Inst Allergol, Berlin, Germany

[4] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[5] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[6] UCLA, Sch Med, Dept Med Dermatol, Los Angeles, CA USA

[7] Galderma Labs, Dallas, TX USA

[8] Galderma R&D, Zug, Switzerland

[9] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD USA

[10] Univ Maryland, Maryland Itch Ctr, Sch Med, Baltimore, MD USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

efficacy; nemolizumab; prurigo nodularis; pruritus; safety; TRIAL;

D O I：

10.1093/bjd/ljae266.046

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

672

引用

页码：47 / 48

页数：2

共 50 条

[41] Dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid asthma requiring treatment: Analysis from two pooled phase 3 trials (liberty ad solo 1&2)
Beck, L. A.
Deleuran, M.
Guttman-Yassky, E.
Kingo, K.
Chen, Z.
Graham, N. M. H.
Pirozzi, G.
Eckert, L.
Gadkari, A.
Ardeleanu, M.
ALLERGY, 2018, 73 : 76 - 77
[42] Cardiovascular Safety of Glycopyrronium in Patients With Moderate-to-Severe COPD: Pooled Analysis From the GEM1, GEM2, FLIGHT1, and FLIGHT2 Studies
Kerwin, Edward
Laforce, Craig
Pedinoff, Andrew
Di Giovanni, Robert
Jessop, Nicola
Henley, Michelle
D'Andrea, Peter
CHEST, 2015, 148 (04)
[43] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Eric L. Simpson
Dermatology and Therapy, 2017, 7 : 243 - 248
[44] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Simpson, Eric L.
DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
[45] Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
Topf, Joel
Wooldridge, Thomas
McCafferty, Kieran
Schomig, Michael
Csiky, Botond
Zwiech, Rafal
Wen, Warren
Bhaduri, Sarbani
Munera, Catherine
Lin, Rong
Jebara, Alia
Cirulli, Joshua
Menzaghi, Frederique
KIDNEY MEDICINE, 2022, 4 (08)
[46] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
Warren, R. B.
Cather, J.
Ohtsuki, M.
Bleakman, A. Potts
Burge, R.
Zhu, B.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
[47] Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
Blauvelt, Andrew
Ardern-Jones, Michael R.
Bieber, Thomas
Hong, Chih-Ho
Chu, Chia-Yu
Liu, Meng
Yang, Yang
Ladizinski, Barry
Teixeira, Henrique D.
Calimlim, Brian M.
Thyssen, Jacob P.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
[48] Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
Puig, L.
Tsai, T. -F.
Bhutani, T.
Uy, J.
Ramachandran, P.
Song, M.
You, Y.
Gooderham, M.
Lebwohl, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : 1744 - 1749
[49] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
Thaci, D.
Jullien, D.
Egeberg, A.
Carrascosa, J. M.
Wu, J. J.
Pau-Charles, I.
Gisondi, P.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
[50] The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
Silverberg, J. I.
Thyssen, J. P.
Costanzo, A.
Calimlim, B. M.
Tenorio, A. R.
Chen, N.
Gooderham, M. J.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E126 - E127

← 1 2 3 4 5 →